Phase II/III Study of the Safety and Efficacy of BAT1308 in Combination With Platinum-containing Chemotherapy for First-line Treatment of Advanced or Recurrent Mismatch Repair Protein-deficient (dMMR) Endometrial Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BAT 1308 (Primary) ; Carboplatin; Paclitaxel
Indications Carcinoma; Endometrial cancer
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Bio-Thera Solutions

Most Recent Events

18 Oct 2024 Planned End Date changed from 1 Oct 2027 to 31 Dec 2024.
18 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 30 Nov 2024.
18 Oct 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight